Cefprozil: A review

Indian Journal of Pediatrics

Volumn 70, Issue 5, 2003, Pages 395-400

  Bhargava, Sumit ^a   Lodha, Rakesh ^a   Kabra, S K ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Cefprozil; Cephalosporins

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAMASE; CEFACLOR; CEFADROXIL; CEFALEXIN; CEFDINIR; CEFETAMET; CEFIXIME; CEFPODOXIME PROXETIL; CEFPROZIL; CEFRADINE; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CEPHEM DERIVATIVE; CLARITHROMYCIN; ERYTHROMYCIN; LORACARBEF; MACROLIDE; METICILLIN; PENICILLIN V POTASSIUM;

AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANTIMICROBIAL ACTIVITY; ARTHROPATHY; BACTERIAL INFECTION; BRONCHITIS; CHRONIC BRONCHITIS; DIARRHEA; DISEASE EXACERBATION; DRUG ACTIVITY; DRUG MECHANISM; DRUG SAFETY; ENZYME STABILITY; FEVER; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MINIMUM INHIBITORY CONCENTRATION; OTITIS MEDIA; PATHOGENESIS; PHARYNGITIS; RASH; REVIEW; SERUM SICKNESS; SIDE EFFECT; SINUSITIS; SKIN INFECTION; SUPERINFECTION; TASTE PREFERENCE; TONSILLITIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 0038512554     PISSN: 00195456     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02723613     Document Type: Review

References (41)

1. Thornsberry C. Review of the in vitro anti bacterial activity of Cefprozil, a new oral cephalosporin. Clin Infect Dis 1992; 149(supp12): S189-S194.
2. Gainer RB. Cefprozil, a new cephalosporin, its.use in various clinical trials. South Med J 1995; 88: 338-346.
3. Wiseman LR, Benfield P. Cefprozil. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential. Drugs 1993; 45: 295-317.
4. Thornberry C, Brown SD, Yee C et al. Increasing penicillin resistance in Streptococcus pneumoniae in the US effect on susceptibility to oral cephalosporins. Infect Med 1993; 10(suppl D):15-24.
5. Fung-Tomc JC, Huczko E, Stickle T et al. Antibacterial activities of Cefprozil compared with those of 13 oral cephems and 3 macrolides. Antimicrob Agents Chemother 1995; 39: 533-538.
6. Wise R. Comparative microbiological activity and pharmacokinetics of Cefprozil. Eur J Clin Microbiol Infect Dis 1994; 13: 839-845.
7. Cappelletty DM, Rybak M. Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection model. Antimicrob Agents and Chemother 1996; 40: 1148-1152.
8. Barbhaiya RH, Gleason CR, Shyu WC et al. Phase I study of single-dose BMY-28100, a new oral cephalosporin. Antimicrob Agents Chemother 1990; 34: 202-205.
9. Barbhaiya RH, Shukla UA, Gleason CR et al. Phase I study of multiple dose cefprozil and comparison with cefaclor. Antimicrob Agents Chemother 1990; 34: 1198-1203.
10. Barbhaiya RH, Shukla UA, Gleason CR et al. Comparison of the effects of food on the pharmacokinetics of cefprozil and cefaclor. Antimicrob Agents Chemother 1990; 34: 1210-1213.
11. Nagano K, Maeda H, Yanagi T et al. Pharmacokinetic and clinical studies of cefprozil fine granules in children. Jpn J Antibiot 1992; 45: 1736-1744.
12. Barriere SL. Pharmacology and pharmacokinetics of cefprozil. Clin Infect Dis 1992; 14 Suppl 2: S184-S188.
13. Shyu WC, Wilber RB, Pittman KA, Garg DC, Barbhaiya RH. Pharmacokinetics of cefprozil in healthy subjects and patients with hepatic impairment. J Clin Pharmacol 1991; 31: 372-376.
14. Barbhaiya RH, Shukla UA, Gleason CR, Shyu WC, Wilber RB, Pittman KA. Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration. Antimicrob Agents Chemother 1990; 34: 1204-1209.
15. Shyu WC, Reilly J, Campbell DA, Wilber RB, Barbhaiya RH. Penetration of cefprozil into tonsillar and adenoidal tissues. Antimicrob Agents Chemother 1993; 37: 1180-1183.
16. Shyu WC, Haddad J, Reilly J et al. Penetration of cefprozil into middle ear fluid of patients with otitis media. Antimicrob Agents Chemother 1994; 38: 2210-2212.
17. Van den Wijngaart W, Verbrugh H, Theopold HM et al. A non comparative study of Cefprozil at 2 dose levels in the treatment of acute uncomplicated bacterial sinusitis. Clin Ther 1992; 14: 306-313.
18. Simon MW. A prospective randomised study comparing the efficacy of amoxicillin clavulanate, erythromycin sulfisoxazole, cefaclor and Cefprozil in treating acute sinusitis of childhood. Adv Ther 1997; 14: 64-72.
19. McCarty J M, Renteria A. Treatment of pharyngitis and tonsillitis with cefprozil: review of three multicenter trials. Clin Infect Dis 1992:14 (suppl2): S224-S230.
20. Milatovic D, Adam D, Hamilton H, Materman E. Cefprozil vs. Penicillin V in treatment of streptococcal tonsillo-pharyngitis. Antimicrob Agents Chemother 1993; 37: 1620-1623.
21. McCarty JM, Renteria A, Doyle CA, Durham SJ, Hamilton H, Wilber RB. Cefprozil vs cefaclor in the treatment of pharyngitis and tonsillitis. Infect Med 1992; 9 (suppl C): 33-43.
22. Brook I, Aronovitz GH, Pichichero ME. Open-Label, parallel group, multicenter, randomized study of cefprozil versus erythromycin in children with group A streptococcal pharyngitis/tonsillitis. Clin Ther 2001; 23: 1889-1900.
23. Arguedas AG, Zaleska M, Stutman HR, Blumer JL, Hains CS. Comparative trial of Cefprozil Vs. amoxicillin clavulanate potassium in the treatment of children with acute otitis media with effusion. Pediatr Infect Dis J 1991; 10: 467-468.
24. Poole JM, Rosenberg R, Aronovitz GH et al. Cefprozil Vs cefixime and cefaclor in otitis media in children. Infect Med 1992; 9(suppl E): 21-32.
25. Stutman HR, Arguedas AG. Comparison of cefprozil with other antibiotic regimens in the treatment of children with acute otitis media. Clin Infect Dis 1992: 14 (suppl 2): S204-S208.
26. Aronovitz GH, Doyle CA, Durham Sj, Wilber RB, Materman E, Simonson C. Cefprozil vs. Amoxicillin clavulanate in the treatment of acute otitis media. Infect Med 1992; 9 (suppl C): 19-32.
27. Gehanno P, Berche P, Boucot I et al. Comparative efficacy and safety of cefprozil and amoxycillin clavulanate in the treatment of acute otitis media in children. J Antimicrob Chemother 1994; 33: 1209-1218.
28. Aronovitz G. Treatment of upper and lower respiratory tract infections: clinical trials with cefprozil. Pediatr Infect Dis J 1998; 17(Suppl 8): S83-S88.
29. Pelletier LL Jr. Review of the experience with cefprozil for the treatment of lower respiratory tract infections. Clin Infect Dis 1992; 14 (Suppl 2): S238-S243.
30. Ball P. Efficacy and safety of cefprozil versus other beta-lactam antibiotics in the treatment of lower respiratory tract infections. Eur J Clin Microbiol Infect Dis 1994; 13: 851-856.
31. Barbarash RA, Solomon E, Thieneman A et al. Cefprozil vs. amoxicillkn clavulanate in mild to moderate lower respiratory tract infections: focus on bronchitis. Infect Med 1992; 9 (suppl E): 40-47.
32. Wilber RB, Hamilton H, Leroy A et al. Cefprozil vs. cefaclor in the treatment of lower respiratory tract infections: a focus on bronchitis. Infect Med 1992; 9 (suppl E): 33-39.
33. Bonnet JP, Ginsberg D, Nolen TM et al. Cefprozil vs. Cefuroxime Axetil in mild to moderate lower respiratory tract infections: a focus on bronchitis. Infect Med 1992; 9 (suppl E): 48-56
34. Solomon E, McCarty JM, Morman MR et al. Comparison of cefprozil and amoxicillin/clavulanate potassium in the treatment of skin and skin structure infections in adults. Adv Ther 1992; 9: 156-165.
35. Parish LC, Doyle CA, Durham SJ, Wilber RB. Cefprozil versus cefaclor in the treatment of mild to moderate skin and skin structure infections. Clin Ther 1992; 14: 458-469.
36. Trujillo M, Ehrett S, Hoyt-Sehnert MJ, Shelton S, McCracken GH Jr. Safety and efficacy of cefprozil as part of a parenteral-oral antibiotic regimen for the treatment of suppurative skeletal infections in children. Clin Infect Dis 1996 Oct; 23(4): 843.
37. Christenson JC, Gooch WM, Herrod JN, Swenson E. Comparative efficacy and safety of cefprozil and cefaclor in the treatment of acute uncomplicated urinary tract infections. J Antimicrob Chemother 1991; 28: 581-586.
38. Iravani A, Doyle CA, Durham SJ, Wilber RB. Cefprozil versus cefaclor in the treatment of acute and uncomplicated urinary tract infections. Cefprozil Multicenter Study Group. Clin Ther 1992; 14: 314-326.
39. th ed. Philadelphia; Mosby, 2000: pp 662.
40. Wilber RB, Doyle CA, Durham SJ, Conetta BJ, DeGraw SS, Leigh A. Safety profile of cefprozil. Clin Infect Dis 1992; 14: S264-S271.
41. Lower N, Kearns GL, Young RA, Wheeler JG. Serum sickness like reactions associated with cefprozil therapy. J Pediatr 1994; 125: 325-328.